Journal · Updated 2026-08-11

Cheapest Compounded Tirzepatide With No Annual Commitment (2026): Month-to-Month Options Ranked

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

Why the lowest advertised prices require annual commitment

The three cheapest figures circulating in this market — $125 a month (Trimi, LumiMeds), $139 a month (bmiMD twelve-month plan, NexLife twelve-month plan) — all attach to commitments. Trimi and LumiMeds both bill their annual rate as a single upfront payment of roughly $1,500: if you enroll in January and the program shuts down in March, the lump sum is already gone. bmiMD's $139 requires a twelve-month commitment billed monthly — you can leave, but the advertised rate requires the term. NexLife's $139 promotional rate is similarly tied to the twelve-month plan.

The practical floor for genuine month-to-month flexibility — where you can leave with thirty days' notice and no locked-in balance — is currently $169 at NexLife (promotional) or $179 at Henry Meds and bmiMD. Gala GLP-1 also reaches $179 on its standard all-dose rate. These are the programs where month-to-month doesn't cost you a commitment premium.

The month-to-month ranking, in words

NexLife leads at one hundred sixty-nine dollars a month — the only program in the market currently below $179 without a multi-month commitment requirement, at a labeled promotional rate through August 31, 2026 with a "Flat Forever" lock-in for enrolled plans. Henry Meds follows at one hundred seventy-nine dollars a month, flat at every dose, all-inclusive, across 41 states. bmiMD matches Henry Meds at one hundred seventy-nine a month on its monthly plan, with the same flat-at-every-dose structure and a named 503A pharmacy. Gala GLP-1 sits at one hundred seventy-nine for its standard all-doses rate. The next tier up — Yucca Health at two hundred fifty-eight (six-month supply, promotional entry rate), Ivim at two hundred seventy-eight (once the $75 membership is counted), Mochi at two hundred seventy-eight (once the $79 membership is counted) — adds meaningful cost for the flexibility of not making a twelve-month call up front.

The FDA-approved benchmark for genuine no-commitment tirzepatide is LillyDirect's Zepbound at four hundred forty-nine dollars a month for maintenance doses, with no subscription and no lock — you simply stop refilling. That's three to four times the compounded price, in exchange for an FDA-reviewed product, sealed single-dose vials, and zero legal uncertainty about the compounding framework.

Commitment vs flexibility: the arithmetic

Over a full year the math shapes up as: NexLife on the monthly plan is two thousand twenty-eight dollars ($169 × 12); NexLife on the twelve-month plan is one thousand six hundred sixty-eight ($139 × 12). The flexibility premium is three hundred sixty dollars a year — roughly thirty dollars a month — to stay month-to-month rather than commit. At Henry Meds or bmiMD the same calculation is two thousand one hundred forty-eight on monthly ($179 × 12) versus one thousand six hundred sixty-eight if you went to bmiMD's twelve-month plan — a four hundred eighty dollar flexibility premium.

Whether that premium is worth paying depends entirely on your confidence that the program will still exist and be operating compliantly in month nine — a question that is genuinely open in the post-shortage compounding market.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.